Johnson & Johnson $JNJ is Ninety One UK Ltd’s 7th Largest Position

Ninety One UK Ltd reduced its stake in Johnson & Johnson (NYSE:JNJ) by 5.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,640,116 shares of the company’s stock after selling 376,048 shares during the period. Johnson & Johnson makes up about 2.7% of Ninety One UK Ltd’s investment portfolio, making the stock its 7th biggest holding. Ninety One UK Ltd owned approximately 0.28% of Johnson & Johnson worth $1,231,210,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $27,000. Clayton Financial Group LLC acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $28,000. Semmax Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $35,000. Finally, Signature Resources Capital Management LLC boosted its stake in shares of Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $207.26 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a market cap of $499.35 billion, a price-to-earnings ratio of 20.01, a PEG ratio of 2.13 and a beta of 0.34. The stock has a 50 day moving average of $201.17 and a 200-day moving average of $182.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analysts Set New Price Targets

Several research firms recently issued reports on JNJ. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Morgan Stanley lifted their target price on Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. UBS Group increased their price target on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Finally, Sanford C. Bernstein upped their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $211.25.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.